Flash Finance
Market closed13 Nov close Nifty 5025,144.30-0.61% Sensex81,592.45-0.39% Bank Nifty61,034.10-0.79% Midcap 15022,681.25-0.35% Smallcap 25017,940.55-0.30% Nifty IT31,931.15-0.72% India VIX15.78-5.06%
Follow Flash Finance FollowTelegram

Shukra Pharmaceuticals LimitedSHUKRAPHARCorporate

Pharmaceuticals Latest results: Sep 2026 2 quarters of data
Consolidated Standalone
₹82.23
MCap ₹3,639 Cr
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹44 Cr
Sales · Sep 2026
₹19 Cr
Operating Profit · Sep 2026
42.3%
OPM % · Sep 2026
₹13 Cr
Net Profit · Sep 2026
₹0.29
EPS · Sep 2026

📝 Shukra Pharmaceuticals Limited — results explained

Quarter ended September 2026 (Q2 FY27)

Shukra Pharmaceuticals Limited reported revenue of ₹44 crore for the quarter ended September 2026 (Q2 FY27), and up 87.9% sequentially over the June 2026 quarter.

Net profit stood at ₹13 crore. Earnings per share (EPS) came in at ₹0.29.

Operating profit stood at ₹19 crore — an operating margin (OPM) of 42.3%.

Valuation snapshot

At the current price of ₹82.23, SHUKRAPHAR has a market capitalisation of ₹3,639 crore.

Within the Pharmaceuticals industry, it is the 4th-largest of the 84 companies we track by market value.

Related 📈 RSI Overbought Stocks📈 Stocks Near 52-Week High📈 Strong Trend Stocks (ADX > 25)📈 Stocks Above Anchored VWAP 🏭 Pharma sector

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹3,639 Cr
Current Price ?
₹82.2
P/E ?
N/A
Industry P/E ?
24.70
P/B ?
30.87
P/S ?
N/A
P/FCF ?
N/A
Enterprise Value ?
₹3,661 Cr
EV/EBITDA ?
N/A
PEG ?
N/A
Earnings Yield ?
N/A
Dividend Yield ?
N/A
Profitability & Returns
Sales (TTM) ?
N/A
OPM ?
N/A
Profit after tax (TTM) ?
N/A
EPS (TTM) ?
N/A
ROCE ?
N/A
ROE ?
N/A
ROA ?
N/A
Growth
Sales — latest qtr ?
₹44 Cr
PAT — latest qtr ?
₹13 Cr
YoY qtr sales growth ?
N/A
YoY qtr profit growth ?
N/A
Sales growth (3y) ?
N/A
Sales growth (5y) ?
N/A
Profit growth (3y) ?
N/A
Profit growth (5y) ?
N/A
Financial Health
Debt ?
₹22 Cr
Debt to Equity ?
0.19
Interest Coverage ?
N/A
Ownership
Promoter holding ?
N/A
Change in promoter holding ?
N/A
FII holding ?
N/A
DII holding ?
N/A
Market
Return 3 months ?
98.5%
Return 6 months ?
98.5%

🗓️ Quarterly results (2 quarters · ₹ Cr)

same fiscal quarter as Sep bestweakest per row · for costs (interest, NPAs) low is best
Metric Jun 2026Sep 2026 YoY % QoQ %
Sales 2444 — +87.9%
Operating Profit 1919 — -2.3%
Other Income 11 — +6.0%
Interest 00 — -22.7%
Depreciation 11 — +3.1%
Profit Before Tax 1818 — -1.9%
Net Profit 1313 — -1.9%
EPS 0.300.29 — -3.3%
OPM % 81.4% 42.3% — -48.0%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Annual rollup not yet available We need at least 3 quarters of a fiscal year to compute annual figures. This symbol does not yet have a complete fiscal year in our database.

🏛️ Balance Sheet (latest 1 periods)

Metric Sep 2026 % Chg
Equity Capital 44 —
Reserves 74 —
Borrowings 22 —
Other Liabilities 35 —
Total Liabilities 175 —
Fixed Assets 21 —
CWIP 26 —
Other Assets 128 —
Total Assets 175 —

📦 Working Capital (latest 1 periods)

Metric Sep 2026 % Chg
Inventories 23 —
Trade Receivables 39 —
Trade Payables 13 —

💧 Half-year Cash Flow (latest 1 periods)

Metric Sep 2026 % Chg
Cash from Operating Activity 0 —
Cash from Investing Activity -15 —
Cash from Financing Activity 20 —
Net Cash Flow 5 —

⚖️ Peer comparison

Industry: Pharmaceuticals · top 25 of 84 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% ROE% ROCE% D/E Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SUDEEPPHRM Sudeep Pharma ₹1,033.30 11,671 61.8 709 189 35.4% 26.7% 19.8% — 0.20 — — 20.9% 10.8%
2 SPARC Sun Pharma ₹185.08 6,006 3.7 1,931 1,636 84.7% 84.7% 113.4% 164.0% 0.00 2512.3% 553.9% 282.1% 67.8%
3 GUJTHEM Gujarat Themis ₹412.60 5,370 92.3 173 48 47.3% 27.8% — — — 8.6% -6.1% 21.6% 23.0%
4 SHUKRAPHAR Shukra Pharmaceuticals ₹83.70 3,704 — — — — — — — 0.19 — — — —
5 539997 Kwality Pharmaceuticals ₹2,652.10 3,475 28.7 624 96 25.6% 15.3% — — — 35.7% 71.8% 63.3% 107.3%
6 524632 Shukra Pharmaceuticals ₹80.95 2,407 72.3 113 50 62.8% 43.9% — — — 74.0% 130.1% 651.8% 572.8%
7 539730 Fredun Pharmaceuticals ₹827.85 2,065 25.4 870 53 15.0% 6.1% — — — 40.1% 90.0% 84.6% 88.3%
8 506414 Fermenta Biotech ₹552.60 1,347 31.5 513 50 16.2% 9.7% — — — 11.9% -6.6% 2.1% -47.6%
9 FERMENTA Fermenta Biotech ₹465.00 1,333 23.9 503 55 17.5% 10.9% 13.2% — 0.26 — — 1.9% -47.7%
10 AHCL Anlon Healthcare ₹24.66 1,311 31.6 280 42 24.5% 14.9% — — — — — — —
11 541096 Bharat Parenterals ₹1,525.00 1,045 — 395 -10 8.4% -2.4% — — — 1.5% 37.5% 110.9% 237.4%
12 540737 Shree Ganesh ₹796.30 844 84.4 92 12 27.6% 13.2% — — — 0.7% -23.0% -23.2% -67.1%
13 AMANTA Amanta Healthcare ₹163.87 636 34.8 303 18 20.5% 6.0% — — — — — 17.3% 301.7%
14 500422 Transchem Ltd-$ ₹38.00 474 5.8 — 8 — — — — — -100.0% -17.8% — 198.0%
15 HALEOSLABS Haleos Labs ₹1,525.00 461 23.5 334 11 10.7% 3.2% 4.8% — 0.62 -3.2% -4.9% 12.3% -72.6%
16 524731 Jenburkt Pharmaceuticals ₹865.75 439 11.6 172 33 23.3% 19.3% — — — 11.8% 6.1% 5.0% 2.1%
17 543616 Trident Lifeline ₹279.85 363 11.0 166 31 26.2% 18.4% — — — — — 117.1% 134.7%
18 512600 Astal Laboratories ₹75.00 308 32.3 170 10 8.8% 5.7% — — — 142.9% -9.0% 56.0% 77.4%
19 524828 BDH Industries ₹336.80 300 17.0 101 11 14.4% 11.2% — — — 44.3% 16.6% 9.4% -12.9%
20 500009 Ambalal Sarabhai ₹38.73 297 20.1 219 15 7.6% 6.7% — — — 3.1% 261.1% 30.8% 220.5%
21 524790 Everest Organics ₹159.20 251 31.7 188 5 10.1% 2.6% — — — 23.0% 527.7% -5.1% -31.1%
22 532039 Zenotech Laboratories ₹64.90 238 — 41 -4 8.1% -10.5% — — — 1.3% -119.2% -36.4% -206.3%
23 530163 Kerala Ayurveda ₹310.20 225 — 126 -26 -13.1% -20.4% — — — 9.0% -16.8% 2.6% 4.2%
24 531569 Sanjivani Paranteral ₹199.95 221 30.4 70 8 15.8% 11.5% — — — -7.6% -14.4% 24.5% 35.0%
25 531739 Gennex Laboratories ₹13.87 215 19.0 183 21 14.4% 11.3% — — — 24.9% 15.5% 16.6% -6.9%
❓ Frequently asked questions
What was Shukra Pharmaceuticals Limited's revenue in Q2 FY27?
Shukra Pharmaceuticals Limited reported revenue of ₹44 crore for the quarter ended September 2026 (Q2 FY27), and up 87.9% sequentially over the June 2026 quarter.
What was Shukra Pharmaceuticals Limited's net profit in Q2 FY27?
Net profit stood at ₹13 crore. Earnings per share (EPS) came in at ₹0.29.
What is SHUKRAPHAR's market capitalisation and P/E ratio?
At the current price of ₹82.23, SHUKRAPHAR has a market capitalisation of ₹3,639 crore.
TTM ends N/A. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI